InnoCan Pharma Corporation is a pharmaceutical technology company founded in 2018 and headquartered in Calgary, Canada. It specializes in innovative drug delivery platforms that combine cannabidiol (CBD) with other pharmaceutical ingredients to treat chronic pain, epilepsy, and other medical conditions. Its proprietary synthetic CBD-loaded liposome injection technology allows precise dosing and sustained release of CBD, aiming to improve therapeutic outcomes and reduce reliance on opioids. The company operates two main segments: pharmaceuticals—which include CBD-integrated pharmaceuticals and topical products for both human and animal health—and consumer wellness, encompassing a broad range of self-care and beauty products, some non-CBD. Innocan holds multiple worldwide patents on its liposomal cannabinoid technologies and is engaged in regulatory processes with the FDA and other agencies. Its business model focuses on strategic partnerships and global commercialization of its cannabinoid-based therapies and wellness offerings, highlighting its role in advancing cannabinoid science within the pharmaceuticals and biotech sector.